Mitochondrial DNA copy number (mtDNA-CN), a measure of the number of mitochondrial genomes per cell, is a minimally invasive proxy measure for mitochondrial function and has been associated with several aging-related diseases. Although quantitative real-time PCR (qPCR) is the gold standard method for measuring mtDNA-CN, mtDNA-CN can also be measured from genotyping microarray probe intensities and DNA sequencing read counts. To conduct a comprehensive examination on the performance of these methods, we use known mtDNA-CN correlates (age, sex, white blood cell count, Duffy locus, incident cardiovascular disease) to evaluate mtDNA-CN calculated from qPCR, two microarray platforms, as well as whole genome (WGS) and whole exome sequence data across 1,085 participants from the Atherosclerosis Risk in Communities (ARIC) study and 3,489 participants from the Multi-Ethnic Study of Atherosclerosis (MESA). We observe mtDNA-CN derived from WGS data is significantly more associated with known correlates compared to all other methods (p < 0.001).
Introduction
Mitochondrial dysfunction has long been known to play an important role in the underlying etiology of several aging-related diseases, including cardiovascular disease (CVD), neurodegenerative disorders and cancer 1 . As an easily measurable and accessible proxy for mitochondrial function, mitochondrial DNA copy number (mtDNA-CN) is increasingly used to assess the role of mitochondria in disease. Several population-based studies have shown higher levels of mtDNA-CN to be associated with decreased incidence for CVD and its component parts: coronary artery disease (CAD) and stroke 2, 3 ; neurodegenerative disorders such as Parkinson's and Alzheimer's 4, 5 ; as well as several types of cancer including breast, kidney, liver and colorectal [6] [7] [8] . Furthermore, mtDNA-CN measured from peripheral blood has consistently been shown to be higher in women, decline with age, and correlate negatively with white blood cell (WBC) count [9] [10] [11] .
Although the mtDNA-CN field is relatively young, the number of publications has been steadily increasing at an average rate of 12% per year since 2015 12 . However, there has yet to be a rigorous examination of the various methods for measuring this novel phenotype and the factors which may influence its accurate estimation. Without such an examination, studies may be severely underestimating or misrepresenting the relationship of mtDNA-CN with their traits of interest.
Quantitative real-time PCR (qPCR) has been the most widely used method for measuring mtDNA-CN, partly due to its low cost and quick turnaround time. However, recent work has demonstrated the feasibility of accurately measuring mtDNA-CN from preexisting microarray, whole exome sequencing (WES) and whole genome sequencing (WGS) data 2, 10, 13 . With these advances, it is important for the field to evaluate these methods in the context of the current gold standard.
In addition to the method for determining mtDNA-CN, it is important to consider the impact of DNA extraction method on mtDNA-CN, particularly due to the small size and circular nature of the mitochondrial genome. Previous research has shown organic solvent extraction is more accurate than silica-based methods at measuring mtDNA-CN, which is unsurprising as column kit parameters are typically optimized for DNA fragments ≥ 50 Kb 14 . However, as all DNA extraction methods have bias in the DNA which they target, measuring mtDNA-CN from direct cell lysate may prove to be a more accurate method.
In the present study, we assess the relative performance of various methods for measuring mtDNA-CN and the effects of DNA extraction on mtDNA-CN estimation accuracy. We leverage mtDNA-CN calculated across 4,574 individuals from two prospective cohorts, the Atherosclerosis Risk in Communities study (ARIC) and the Multi-Ethnic Study of Atherosclerosis study (MESA). Using mtDNA-CN estimates calculated from qPCR, WES, WGS, and two microarray platforms -the Affymetrix Genome-Wide Human SNP Array 6.0 and the Illumina HumanExome BeadChip genotyping array -we compare associations for known correlates of mtDNA-CN including age, sex, white blood cell count, the Duffy locus and incident CVD to determine the optimal method for calculating copy number. We additionally determined the reproducibility of mtDNA-CN measurements in vitro from three separate DNA extraction methods: silica-based column selection, organic solvent extraction (phenol-chloroform-isoamyl alcohol), and measuring mtDNA-CN from direct cell lysis without performing a traditional DNA extraction. We hypothesized that mtDNA-CN calculated from WGS data would outperform other estimation methods and mtDNA-CN measured from direct cell lysate would be more accurate than traditional DNA extraction methods.
Methods

Study Populations
The ARIC study recruited 15,792 individuals between 1987 and 1989 aged 45 to 65 years from 4 US communities. DNA for mtDNA-CN estimation was collected from different visits and was derived from buffy coat using the Gentra Puregene Blood Kit (Qiagen). Our analyses were 
Measurement of mtDNA-CN
qPCR mtDNA-CN was determined using a multiplexed real time qPCR assay as previously described 11 . Briefly, the cycle threshold (Ct) value of a mitochondrial-specific (ND1) and nuclear- 
WES
Whole exome capture was performed using Nimblegen's VChrome2.1 (Roche) and sequencing was performed on the Illumina HiSeq 2000. Sequence reads were aligned using BurrowsWheeler Aligner (BWA) 16 to the hg19 reference genome. Variant calling, and quality control were performed as previously described 17 . mtDNA-CN was calculated using the mitoAnalyzer software package, which determines the observed ratios of sequence coverages between autosomal and mtDNA 18, 19 .
Due to large batch effects observed in our raw mtDNA-CN calls, alignment summary, insert size, quality score, base distribution, sequencing artifact and quality yield metrics were collected using Picard tools (version 1.87) to take into account differences in capture efficiency as well as sequencing and alignment quality 20 . Picard sequencing summary metrics to incorporate into our final model were selected through a stepwise backwards elimination model (Supp. Table 1 ).
WGS
Whole genome sequencing data was generated at the Baylor College of Medicine Human
Genome Sequencing Center using Nano or PCR-free DNA libraries on the Illumina HiSeq 2000.
Sequence reads were mapped to the hg19 reference genome using BWA 16 . Variant calling and quality control were performed as previously described 21 . A count for the total number of reads in a sample was scraped from the NCBI sequence read archive using the R package RCurl 22 while reads aligned to the mitochondrial genome were downloaded directly through Samtools (version 1.3.1). A raw measure of mtDNA-CN was calculated as the ratio of mitochondrial reads to the number of total aligned reads. Unlike WES, we did not observe large batch effects in our WGS raw mtDNA-CN calls, obviating the need for adjustment for Picard sequencing summary metrics.
Cardiovascular Disease Definition and Adjudication
8
Event adjudication through 2017 in ARIC and 2015 in MESA consisted of expert committee review of death certificates, hospital records and telephone interviews. Incident cardiovascular disease (CVD) was defined as either incident coronary artery disease (CAD) or incident stroke.
Incident CAD was defined as first incident MI or death owing to CAD while incident stroke was defined as first nonfatal stroke or death due to stroke. Individuals in ARIC with prevalent CVD at baseline were excluded from incident analyses.
Genotyping and Imputation
Genotype calling for the WBC count locus was derived from the Affymetrix Genome-wide Human SNP Array 6.0 in ARIC and MESA. Haplotype phasing for both cohorts was performed using ShapeIt 23 and imputation was performed using IMPUTE2 24 . Genotypes were imputed to the 1000G reference panel (Phase I, version 3). Imputation quality for the Duffy locus lead SNP (rs2814778) was 0.946 and 0.92 in ARIC and MESA, respectively.
DNA extraction method
All DNA used in the DNA extraction comparison were derived from HEK293T cells grown in a single 150T flask to minimize variation due to clonality and cell culture procedures. Extraction were performed with 15 replicates each containing one million cells. mtDNA-CN was determined using qPCR as described previously. To account for the inherent variability in mtDNA-CN estimation, qPCR was run in triplicate.
Silica-based Column Extraction
We performed a silica-based column extraction using the AllPrep DNA/RNA Mini Kit (Qiagen)
according to the manufacturer's instructions for fewer than 5 x 10 6 cells. Briefly, HEK293T cells were lysed and the subsequent lysate was pipetted directly onto the DNA Allprep spin column for homogenization and DNA binding. The bound DNA was then washed and eluted.
Organic Solvent Extraction
An aliquot of cells were lysed with 350 µL of RLT Plus Buffer (Qiagen) and one volume of phenol:chloroform:isoamyl alcohol (25:24:1) (PCIAA) was added to the sample and mixed until it turned milky white. The solution was centrifuged and the upper aqueous phase containing DNA was transferred to a separate tube. We proceeded with an ethanol precipitation protocol using 3M sodium acetate to complete the DNA extraction.
Direct Cell Lysis
Cells were pelleted at 500g for 5 minutes and the supernatant was removed. The cell pellet was agitated in 100 µL of QuickExtract DNA Solution (Lucigen) to disrupt the pellet and placed in a thermocycler for 15 minutes at 68°C followed by 10 minutes at 95°C. The cell lysate was then centrifuged at 17,000g for 15 minutes to pellet any insoluble inhibitors and the supernatant was transferred to a clean tube. The supernatant containing DNA was finally diluted 1:30 with water to limit the impact of any soluble inhibitors on qPCR.
Statistical Analyses
Our final mtDNA-CN phenotype for all measurement techniques is represented as the standardized residuals from a linear model adjusting the raw measure of mtDNA-CN for age, sex, DNA collection center, and technical covariates. Additionally, mtDNA-CN in ARIC was adjusted for WBC count, and the 14.9% of individuals with missing WBC data were imputed to the mean. WBC was not available in MESA for the same visit in which the DNA was obtained.
As mtDNA-CN was standardized, the effect size estimates are in units of standard deviations, with positive betas corresponding to an increase in mtDNA-CN. . In ARIC, mtDNA-CN not adjusted for WBC count was used as the independent variable. Single SNP regression models were additionally adjusted for age, sex, sample collection site, and genotyping PCs.
Cox-proportional hazards regression was used to estimate hazard ratios (HRs) for incident CVD outcomes. Follow-up time was defined from DNA collection through death, loss to follow-up, or study end point (through 2017 in ARIC and 2015 in MESA).
Pairwise F-tests were used to test the null hypothesis that the ratio of variances between the DNA extraction methods is equal to one.
All statistical analyses were performed using R (version 3.3.3).
Results
The study included 1,085 participants from ARIC with mtDNA-CN data from the Affymetrix 6.0 microarray, the Illumina Exome Chip microarray, WES, and WGS while MESA included 3,489
participants with mtDNA-CN data available from qPCR, the Affymetrix 6.0 microarray, and the Illumina Exome Chip microarray (combined N = 4,574). The mean age of study participants was 61.4 years (ARIC, 57.1 years; MESA 62.7 years), 55.3% of participants were female (n = 2,528), and 46.4% of participants were black (n = 2,124) ( Table 1) . While the Affymetrix and Illumina Exome Chip arrays were run in both cohorts, at the time of analysis WES and WGS were unique to ARIC and qPCR was unique to MESA.
mtDNA-CN Estimation Method Comparison
To determine the optimal method for measuring mtDNA-CN, we ranked the performance of each technique based on strength of the association, as measured by p values, with the relevant mtDNA-CN correlate (Supp. (Table 2) .
To additionally quantify performance, we created a scoring system for each method using negative log transformed p values standardized to the least significant method for each correlate. These values were then summed across the correlates for each method to achieve an overall rating of performance (Supp. Table 3 ). These ratings were compared to 1,000
permutations of a random sampling of the standardized and transformed p values for each correlate across the different estimation techniques. In ARIC, WGS had a significantly higher performance score compared to all other methods (p < 0.002) while the Illumina Exome Chip had a significantly lower score (p = 0.03) (Supp Fig 1A) . In MESA, Affymetrix had a significantly higher score than qPCR and the Illumina Exome Chip (p = 0.002) (Supp Fig 1B) . When removing the contribution of WGS in ARIC, the Affymetrix array had a significantly higher score than the Illumina Exome Chip and WES (p = 0.01) (Supp Fig 1C) .
As WGS and Affymetrix performed similarly, we sought to further parse out their performance by evaluating the 2,746 ARIC samples which contained mtDNA-CN from both platforms. On average, WGS performed 2.2 orders of magnitude more significantly than the Affymetrix array (Supp Table 4 ).
DNA Extraction Comparison
Raw mitochondrial estimates from qPCR were mean-zeroed to the plate average and the mean value across the triplicate plates was used to determine the variance across the 15 replicates for each method (Fig 1) . The variance for our novel Lyse method was significantly lower at 0.02 ). Additionally, our findings support previous work 14 demonstrating PCIAA had significantly lower variability compared to the Qiagen Kit (F = 0.29, p = 0.03).
Discussion
We explored several methods for measuring mtDNA-CN in 4,574 self-identified white and black participants from the ARIC and MESA studies. We found mtDNA-CN estimated from WGS read counts and Affymetrix Genome-Wide Human SNP Array 6.0 probe intensities was more significantly associated with known mtDNA-CN correlates compared to mtDNA-CN estimated from WES, qPCR and the Illumina HumanExome BeadChip. When observing the relative performance of these methods, mtDNA-CN calculated from either WGS or Affymetrix array are, respectively, 5.6 and 5.4 orders of magnitude more significant than the current gold standard of qPCR (Fig 2) . These results are not limited to significance as we see similar trends when exploring effect size estimates (Fig 3) . Interestingly, mtDNA-CN measured from two seemingly similar microarray platforms differed drastically (Supp. Fig 2) . However, this finding is unsurprising when exploring the underlying biochemistry of sample preparation for each microarray platform. While the Affymetrix protocol starts with two restriction enzyme digests prior to whole genome amplification (WGA), the Illumina Exome Chip requires WGA with a processive polymerase prior to sonication. As a result, the mitochondrial genome undergoes rolling circle amplification which occurs at a significantly faster rate than linear WGA 27 .
Lower mtDNA-CN has been found to be associated with an increased incidence for several diseases, including end stage renal disease, type 2 diabetes, and non-alcoholic fatty liver disease [28] [29] [30] . However, such studies have relied on mtDNA-CN estimated from qPCR data. Our findings suggest much of the current literature may be severely underestimating disease associations with mtDNA-CN as well as its potential as a predictor of disease outcomes.
Despite this, at <$2 per sample qPCR may remain the principal method for measuring mtDNA-CN due to the prohibitive costs of WGS. As a result, it may be time for the field to start exploring other low cost methods, such as digital droplet PCR, which may improve upon the accuracy of qPCR 31, 32 .
We additionally showed DNA extraction method affects mtDNA-CN estimate reproducibility with copy number measured directly from cell lysate significantly outperforming silica-based column extraction and organic solvent extraction. Although several other studies have explored the impact of DNA isolation protocol on mtDNA-CN estimation 14, 33, 34 , to our knowledge, this is the first study to interrogate the possibility of measuring mtDNA-CN directly from cell lysate. In addition to the superior performance of direct cell lysis, this method is cheaper and has less hands-on time than PCIAA or Qiagen Kit extractions. However, the authors recognize DNA from cell lysate has less downstream utility than traditional DNA extraction procedures potentially limiting its adoption within the mtDNA-CN field when sample availability is limited. Furthermore, it is important to note the various DNA extraction methods resulted in significantly different mtDNA-CN estimates (p = 3.56x10 -11 , 0.02, 2.85x10 -7 for Lyse:PCIAA, Lyse:Qiagen Kit, and PCIAA:Qiagen Kit respectively). As such, when choosing an extraction method, it is important to remain consistent across the study.
In conclusion, our study demonstrates mtDNA-CN calculated from WGS reads or Affymetrix microarray probe intensities significantly improves upon the current gold standard method of qPCR. Furthermore, we show direct cell lysis introduces less variability to mtDNA-CN estimates than popular DNA extraction methods. Despite the relative infancy of using mtDNA-CN as a novel risk marker, these findings highlight the need for the field to adapt to current technologies to ensure disease and trait associations are fully realized with a move toward more accurate microarray and WGS methods. Furthermore, due to the prevalence of qPCR in the literature, the authors recommend re-analyzing trait associations as more WGS data becomes available from large initiatives such as the Trans-Omics for Precision Medicine program.
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Figure 2. Relative overall performance of mtDNA-CN estimation methods
Overall performance for each method scored as mean or median of the negative logtransformed p value across all correlates normalized to the least significant method of each correlate. For ExomeChip and Affymetrix, the mean value across both cohorts was used as the final measure of performance. represented as '*' for P < 0.05, '**' for P < 0.01, and '***' for P < 0.001. WBC, white blood cell.
